Two new clinical trials have recently been opened for recruitment at Linear!

Patients with B-Cell Lymphoma and Chronic Lymphocytic Leukemia will now have the opportunity to enrol (if suitable) to two new clinical trials that have recently opened at Linear Clinical Research.

One of the trials, which is being ran by Prof. Chan Cheah as Principal Investigator (PI), is a first in-human study that uses a drug to block the MALT-1 protein. Dr Katharine Lewis will be tackling the other trial BGB-3111-113 as PI. This interesting trial looks at the drug interaction between a BTK inhibitor Zanubrutinib and other medications used to treat health problems. Patients in both trials will take a tablet by mouth daily until it stops working or patients experiences unacceptable side effects.

For more details of the trial, see links below:

MALT-1: https://www.bloodcancerwa.org.au/trial/malt-1/

BGB-3111: https://www.bloodcancerwa.org.au/trial/bgb-3111-113/

Menu